Literature DB >> 28668656

Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area.

Maria L Cristina1, Cristiano Alicino2, Marina Sartini3, Valeria Faccio4, Anna M Spagnolo5, Valerio D Bono6, Giovanni Cassola7, Anna M De Mite8, Maria P Crisalli9, Gianluca Ottria10, Elisa Schinca11, Giuliano L Pinto12, Luigi C Bottaro13, Claudio Viscoli14, Andrea Orsi15, Daniele R Giacobbe16, Giancarlo Icardi17.   

Abstract

In the last decade, carbapenem-resistant Klebsiella pneumoniae (CR-Kp) has become endemic in several countries, including Italy. In the present study, we assessed the differences in epidemiology, management, and mortality of CR-Kp bloodstream infection (BSI) in the three main adult acute-care hospitals of the metropolitan area of Genoa, Italy. From January 2013 to December 2014, all patients with CR-Kp BSI were identified through the computerized microbiology laboratory databases of the three hospitals. The primary endpoints of the study were incidence and characteristics of CR-Kp BSI in hospitals within the same endemic metropolitan area. Secondary endpoints were characteristics of CR-Kp BSI in hospitals with and without internal infectious diseases consultants (IDCs) and 15-day mortality. During the study period, the incidence of healthcare-associated CR-Kp BSI in the entire study population was 1.35 episodes per 10,000 patient-days, with substantial differences between the three hospitals. Patients admitted to the two hospital with internal IDCs were more likely to receive post-susceptibility test combined therapy including carbapenems (77% vs. 26%, p<0.001), adequate post-susceptibility test therapies (86% vs. 52%, p<0.001), and post-susceptibility therapies prescribed by an infectious diseases specialist (84% vs. 14%, p<0.001). Overall, the crude 15-days mortality was 26%. In the final multivariable model, only septic shock at BSI presentation was unfavorably and independently associated with 15-days mortality (odds ratio [OR] 6.7, 95% confidence intervals [CI] 2.6-17.6, p<0.001), while a protective effect was observed for post-susceptibility test combined therapies including a carbapenem (OR 0.11, 95% CI 0.03-0.43, p=0.002). Mortality of CR-Kp remains high. Differences in the incidence of CR-Kp BSI were detected between acute-care centers within the same endemic metropolitan area. Efforts should be made to improve the collaboration and coordination between centers, to prevent further diffusion of CR-Kp.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  BSI; Bloodstream infection; CRKP; Carbapenem-resistant Klebsiella pneumoniae; Epidemiology

Mesh:

Substances:

Year:  2017        PMID: 28668656     DOI: 10.1016/j.jiph.2017.06.003

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  11 in total

1.  Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy.

Authors:  Daniele Roberto Giacobbe; Valerio Del Bono; Malgorzata Mikulska; Giulia Gustinetti; Anna Marchese; Federica Mina; Alessio Signori; Andrea Orsi; Fulvio Rudello; Cristiano Alicino; Beatrice Bonalumi; Alessandra Morando; Giancarlo Icardi; Sabrina Beltramini; Claudio Viscoli
Journal:  Infection       Date:  2017-08-30       Impact factor: 3.553

Review 2.  Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Authors:  Moritz Fritzenwanker; Can Imirzalioglu; Susanne Herold; Florian M Wagenlehner; Klaus-Peter Zimmer; Trinad Chakraborty
Journal:  Dtsch Arztebl Int       Date:  2018-05-21       Impact factor: 5.594

3.  Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

Authors:  Yunying Zhu; Tingting Xiao; Yuan Wang; Kai Yang; Yanzi Zhou; Qixia Luo; Ping Shen; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2021-12-14       Impact factor: 4.003

4.  Complete Genome Sequence of Klebsiella pneumoniae Phages SopranoGao, MezzoGao, and AltoGao.

Authors:  Sarah Gao; Sara B Linden; Daniel C Nelson
Journal:  Genome Announc       Date:  2017-11-09

5.  Tigecycline application in a 3-month-old infant with multiple drug resistant Klebsiella pneumonia: a case report.

Authors:  Cheng Peng; Xiaofeng Wang; Jiangwei Zhang; Yi Jiang; Xinlin Hou
Journal:  Gut Pathog       Date:  2018-06-22       Impact factor: 4.181

6.  Is Post-Reprocessing Microbiological Surveillance of Duodenoscopes Effective in Reducing the Potential Risk in Transmitting Pathogens?

Authors:  Maria Luisa Cristina; Marina Sartini; Elisa Schinca; Gianluca Ottria; Chiara Dupont; Palmira Bova; Gianni Coccia; Beatrice Casini; Anna Maria Spagnolo
Journal:  Int J Environ Res Public Health       Date:  2019-12-24       Impact factor: 3.390

7.  Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis.

Authors:  Esther E Avendano; Gowri Raman; Jeffrey Chan; Eilish McCann
Journal:  Antimicrob Resist Infect Control       Date:  2020-12-07       Impact factor: 4.887

8.  Molecular Epidemiology and Drug Resistant Mechanism of Carbapenem-Resistant Klebsiella pneumoniae in Elderly Patients With Lower Respiratory Tract Infection.

Authors:  Chunhong Shao; Wei Wang; Shuang Liu; Zhijun Zhang; Meijie Jiang; Fusen Zhang
Journal:  Front Public Health       Date:  2021-05-20

9.  Clinical and molecular characteristics, risk factors and outcomes of Carbapenem-resistant Klebsiella pneumoniae bloodstream infections in the intensive care unit.

Authors:  Xia Zheng; Jian-Feng Wang; Wang-Lan Xu; Jun Xu; Juan Hu
Journal:  Antimicrob Resist Infect Control       Date:  2017-10-02       Impact factor: 4.887

Review 10.  Carbapenem-Resistant Enterobacteriaceae-Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies.

Authors:  Kristin Ølfarnes Storhaug; Dag Harald Skutlaberg; Bent Are Hansen; Håkon Reikvam; Øystein Wendelbo
Journal:  Antibiotics (Basel)       Date:  2021-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.